Anti-TL1A Monoclonal Antibody, Tulisokibart, Aids Ulcerative Colitis

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Oct 4, 2024.

By Lori Solomon HealthDay Reporter

FRIDAY, Oct. 4, 2024 -- Tulisokibart, a tumor necrosis factor-like cytokine 1A monoclonal antibody, is more effective in inducing clinical remission in patients with moderately to severely active ulcerative colitis than placebo, according to a phase 2 study published in the Sept. 26 issue of the New England Journal of Medicine.

Bruce E. Sands, M.D., from the Icahn School of Medicine at Mount Sinai in New York City, and colleagues randomly assigned 135 patients with glucocorticoid dependence or failure of conventional or advanced therapies for ulcerative colitis to receive intravenous tulisokibart (1,000 mg on day 1 and 500 mg at weeks 2, 6, and 10) or placebo. Cohort 1 included patients regardless of genetic status, and cohort 2 included only 43 patients with a positive test for likelihood of response.

The researchers found that a significantly higher percentage of patients who received tulisokibart had clinical remission than those who received placebo (26 versus 1 percent). Among 75 patients with a positive test for likelihood of response (across cohorts), clinical remission occurred in a higher percentage of patients who received tulisokibart versus those who received placebo (32 versus 11 percent). The incidence of adverse events was similar in the tulisokibart and placebo groups, with most adverse events mild to moderate in severity.

"Additional evaluation and comparisons in larger patient populations are needed to further assess the value of the diagnostic test," the authors write.

The study was funded by Prometheus Biosciences, a subsidiary of Merck, which is developing tulisokibart.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-10-05 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords